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ABSTRACT
Objective: To determine the prevalence of lymphogra-
nuloma venereum (LGV) and non-LGV associated serovars
of urethral and rectal Chlamydia trachomatis (CT) infection
in men who have sex with men (MSM).
Design: Multicentre cross-sectional survey.
Setting: Four genitourinary medicine clinics in the United
Kingdom from 2006–7.
Subjects: 4825 urethral and 6778 rectal samples from
consecutive MSM attending for sexual health screening.
Methods: Urethral swabs or urine and rectal swabs were
tested for CT using standard nucleic acid amplification
tests. Chlamydia-positive specimens were sent to the
reference laboratory for serovar determination.
Main outcome: Positivity for both LGV and non-LGV
associated CT serovars; proportion of cases that were
symptomatic.
Results: The positivity (with 95% confidence intervals) in
rectal samples was 6.06% (5.51% to 6.66%) for non-LGV
CT and 0.90% (0.69% to 1.16%) for LGV; for urethral
samples 3.21% (2.74% to 3.76%) for non-LGV CT and
0.04% (0.01% to 0.16%) for LGV. The majority of LGV was
symptomatic (95% of rectal, one of two urethral cases);
non-LGV chlamydia was mostly symptomatic in the
urethra (68%) but not in the rectum (16%).
Conclusions: Chlamydial infections are common in MSM
attending for sexual health screening, and the majority are
non-LGV associated serovars. We did not identify a large
reservoir of asymptomatic LGV in the rectum or urethra.
Testing for chlamydia from the rectum and urethra should
be included for MSM requesting a sexual health screen,
but serovar-typing is not indicated in the absence of
symptoms. We have yet to identify the source of most
cases of LGV in the UK.
Lymphogranuloma venereum (LGV) has re-
emerged as a significant sexually transmitted
infection (STI) among men who have sex with
men (MSM) in the UK and Europe. Initial out-
breaks and clusters of cases in The Netherlands,
Germany, UK and France have been followed by
reports in several other parts of Europe, North
America and Australia.
1 Before these outbreaks
there were sporadic cases of LGV in the west,
although it was probably under-diagnosed because
of limited diagnostic methods and facilities. LGV
was an established cause of proctitis in MSM but
the prevalence and clinical spectrum of the infec-
tion were unknown.
2 Previous outbreaks of LGV
appear to have been relatively short lived, but there
is increasing evidence that LGV has now become
endemic among MSM in the UK. Between October
2004 and December 2008, the National Reference
Centre identified LGV in 854 isolates (Health
Protection Agency, unpublished data).
The clinical features of recent cases of LGV have
been documented but there are many outstanding
questions about the transmission and persistence
of the infection in the population.
34 The over-
whelming majority of cases have been rectal, with
fewer cases diagnosed from urogenital sites.
Reported risk factors for acquisition have included
HIV infection, other STI, anal enema use, unpro-
tected receptive anal intercourse, attendance at sex
parties, reporting fisting and the use of sex toys.
56
These findings suggest that transmission could be
predominantly rectal-to-rectal via intermediate
carriage on hands or fomites such as toys or enema
equipment. However, this does not explain trans-
mission in those men who only report anal
intercourse where the source is likely to be
urogenital infection.
In the UK, if there was significant asymptomatic
LGV this would not have been detected through
routine channels, since LGV typing is only carried
out on those with clinical syndromes suggestive of
the infection. While urethral testing for chlamydia
is now generally performed in clinics, rectal
screening is not routinely done in all clinics.
7 We
therefore carried out a case finding exercise in
which routine testing for chlamydia was standar-
dised in four clinics in order to estimate the
prevalence of LGV and non-LGV Chlamydia tracho-
matis (CT) in MSM in the UK, and to determine
whether there is a significant amount of asympto-
matic urogenital or rectal LGV infection that may
be acting as a reservoir of undiagnosed and
untreated infection.
METHODS
Unselected MSM attending four genitourinary
medicine (GUM) clinics in the UK for sexual
health screening were tested for urethral and rectal
CT regardless of symptoms. Data collection took
place between 2006 and 2007 for limited time
periods, usually three months, in each clinic. The
clinics were chosen on the basis that they had
already reported substantial numbers of cases of
LGV and served large populations of MSM. They
were already testing MSM for urethral chlamydia,
but rectal testing was generally confined to those
with symptoms. Before the undertaking of this
initiative, CT-positive specimens were only for-
warded to the reference laboratory for LGV typing
if patients met the inclusion criteria—namely,
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someone with LGV.
For the duration of the case finding exercise, all MSM
attending each of the clinics had a rectal swab and a urine or
urethral specimen taken for chlamydia testing, irrespective of
symptoms but according to sexual risk assessment. Rectal and
urethral/urine samples were tested in the local diagnostic
laboratories using either the Probetec Strand Displacement
Assay (SDA, Becton Dickinson, Sparks, MD, USA) or the
Combas Amplicor (Roche Diagnostics Systems, Branchburg, NJ,
USA) for the identification of CT. All samples that tested
positive for CT were sent to the Sexually Transmitted Bacterial
Reference Laboratory (STBRL) for LGV testing using an LGV-
specific real-time polymerase chain reaction (PCR) assay.
8 In one
clinic, only positive rectal samples were forwarded for LGV
typing.
Clinics recorded the numbers of urethral and rectal tests
performed on MSM during the data collection period, and these
were collated with results of chlamydia testing and LGV typing.
For all cases of LGV, clinics were asked to confirm whether or
not the patient had symptoms; for cases of non-LGV CT three
clinics were also able to provide data on symptoms. Whether a
patient was symptomatic was both patient reported (discharge,
tenesmus, rectal bleeding, rectal pain, change in bowel habit,
urethral symptoms) or based on clinical findings (proctitis,
mucous discharge, contact bleeding seen on proctoscopy and
sampling). Proctoscopy was performed in all patients.
Ethics committee approval and individual patient consent
were not obtained as this was considered to be a standard case
finding exercise in the context of an outbreak investigation;
tests performed were in line with existing clinical guidelines;
and routine testing for rectal chlamydia was standard care in
many clinics already and recommended by BASHH guidelines of
2006.
79 Patients were informed of the tests that were being
performed. Data on patients with LGV were collected retro-
spectively as part of case surveillance. Regardless of symptoms,
all CT-positive specimens obtained at these centres were
referred for LGV typing during this period and this was justified
in the context of an epidemic where the rate of symptomatic
LGV in London/Brighton was yet to be determined. Those with
confirmed LGV-positive specimens had these results conveyed
to them and were managed as appropriate at their respective
clinics.
RESULTS
Across the four clinics there were 4825 urethral/urine and 6778
rectal samples from MSM. In these samples the overall
prevalence of CT was 3.25% in the urethra (157 positive tests)
and 6.96% in the rectum (472 positive tests). Table 1 shows
LGV and non-LGV CT positivity for urethral and rectal
specimens overall and by clinic. The majority of CT at both
anatomical sites was attributable to non-LGV strains (99.4% in
the urethra and 87.1% in the rectum). Findings were consistent
across the clinics.
Clinical data were available for all cases of LGV and for all
urethral non-LGV CT infections; clinical data were missing for
110/411 (26.8%) of rectal infections caused by non-LGV CT.
The majority of LGV was symptomatic: 58 of 61 rectal cases
(95%) and one of the two urethral cases. In centre A, two of the
38 cases of rectal LGV were also infected with gonorrhoea; one
was asymptomatic and the other had discharge and proctitis.
Details on co-infections were not available for other centres.
Non-LGV chlamydia was mostly symptomatic in the urethra
(105 of 155 cases, 67.7%) but not in the rectum (49/301, 16.3%).
DISCUSSION
This large study in unselected MSM attending GUM clinics in
London and Brighton shows an estimated prevalence of LGV of
0.90% in the rectum and 0.04% in the urethra, with little
variation across the four centres included in this study. We did
not identify a large reservoir of urethral LGV or of asympto-
matic rectal LGV. We only identified two cases of urethral LGV
and therefore it is not possible to make further generalisations
about the presentation. The majority of cases of LGV in the
rectum were in men with symptoms. Co-infection with
gonorrhoea, for example, existed in a minority of cases in the
one centre where this was documented. Non-LGV chlamydia
was more prevalent and mostly asymptomatic in the rectum
and symptomatic in the urethra.
This is the largest study to date to estimate the prevalence of
LGV in MSM, and has the advantage of including men
attending clinics serving different local populations. The study
is limited by the lack of detailed data on all those who were
screened, and therefore we are unable to provide a true
prevalence estimate, since individuals may have been screened
more than once, and we do not have details of symptoms for all
those screened, or for some patients with chlamydia infection.
The lack of these and related data such as HIV status reflect the
nature of the study: it was established as part of an outbreak
investigation with the aim of identifying undiagnosed cases that
may help with control efforts.
A relatively small proportion of cases (6%) were asympto-
matic, and it seems unlikely that such cases are a major factor in
ongoing transmission. A linked study at another large clinic in
London screened 3076 unselected MSM and found a similar
overall prevalence of LGV with 36 cases (1.17%) including 35
rectal and one urethral.
10 They report a higher proportion of
asymptomatic rectal cases (17% compared with 5% in this
Table 1 Chlamydia trachomatis (CT), lymphogranuloma venereum (LGV) and non-LGV chlamydia positivity in urethral and rectal specimens from MSM
by clinic
Clinic*
Urethral chlamydia Rectal chlamydia
% (95% CI) % (95% CI)
No of
tests All CT LGV Non-LGV CT
No of
tests All CT LGV Non-LGV CT
A 3501 3.26 (2.67 to 3.85) 0.06 (0.01 to 0.14) 3.20 (2.62 to 3.78) 3501 7.21 (6.34 to 8.06) 1.09 (0.75 to 1.43) 6.11 (5.32 to 6.90)
B 933 3.43 (2.26 to 4.60) 3.43 (2.26 to 4.60) 1210 5.87 (4.55 to 7.19) 0.58 (0.15 to 1.01) 5.29 (4.03 to 6.55)
C . . . 1672 7.18 (5.94 to 8.42) 0.60 (0.23 to 0.97) 6.58 (5.39 to 7.77)
D 391 2.81 (1.17 to 4.45) 2.81 (1.17 to 4.45) 395 7.34 (4.77 to 9.91) 1.52 (0.31 to 2.73) 5.82 (3.51 to 8.13)
All 4825 3.25 (2.78 to 3.80) 0.04 (0.01 to 0.16) 3.21 (2.74 to 3.76) 6778 6.96 (6.37 to 7.60) 0.90 (0.69 to 1.16) 6.06 (5.51 to 6.66)
*A, Brighton; B, Mortimer Market; C, Royal Free; D, St Thomas’s.
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Taken together these results do not provide sufficient evidence
to recommend routine screening of all MSM for rectal LGV. The
current recommendation of diagnostic testing for CT with
LGV-typing of CT-positive specimens in men with proctitis, or
contacts of men with LGV, should remain in place. These
findings contrast with reports from The Netherlands where the
majority of LGV cases in some reports have been asympto-
matic.
61 1 Our findings are from men attending GUM clinics
rather than an unselected population sample, but this is
unlikely to explain the discrepancy as they are similar to the
settings for the research in The Netherlands.
We found very little urethral LGV which fits the general
picture of the recent LGV outbreaks in Europe,
11 but also poses
the question of how transmission is being sustained. Early
reports suggested transmission through sex toys or fisting, but
more recent analyses have not supported this association, and
more research into modes of transmission is required.
34There is
insufficient evidence to recommend routine screening of MSM
for urethral LGV. Diagnostic tests for CT with LGV-typing of
CT-positive specimens should be carried out on LGV contacts
and men with signs of genital ulcer adenopathy syndrome or
other suspected LGV disease. The question of how transmission
occurs and what underpins the persistence of LGV will only be
answered by more detailed clinical and epidemiological research.
We have confirmed previous reports of a significant pre-
valence of non-LGV rectal chlamydia in this population. In
contrast to LGV, most of the rectal serotype D-K infection is
asymptomatic. Guidelines from the United States, Canada and
Australia recommend screening MSM for rectal chlamydia
although they do not advise which test to use as none of the
nucleic acid amplification tests (NAATs) are Food and Drug
Administration (FDA) approved or CE marked for rectal
specimens.
12 In the UK there is no recommendation for routine
rectal screening and the decision rests with local clinics and
laboratories. Repeated studies of the performance of NAATs for
CT on rectal samples have shown good validity, and in practice
these tests are being increasingly being used within the UK.
71 3
The lack of approved tests applies equally to the issue of
diagnostic testing, and UK guidelines indicate that NAATs are
the test of choice in the diagnosis of chlamydial proctitis and
LGV. This rather contradictory situation shows the urgency of
developing a good evidence-based guideline on rectal chlamydia
testing.
While the prevalence of rectal LGV is only 1%, it remains an
important pathogen that can lead to severe acute symptoms
and serious sequelae, and may facilitate the transmission of HIV
and hepatitis C.
12 The shift from sporadic outbreaks towards an
endemic infection indicates that more needs to be done in terms
of active case finding, with a low threshold of testing for
chlamydia and LGV in MSM with symptoms, particularly in
men with HIV, and an intensified health promotion campaign
to alert MSM to the possibility of LGV infection.
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Key messages
c There is a sustained outbreak of lymphogranuloma venereum
(LGV) among men who have sex with men (MSM) in the UK.
c LGV was identified in 1% of rectal and ,0.1% of urethral
samples from MSM attending clinics.
c Non-LGV chlamydia was more common, found in 6% of rectal
and 3% of urethral samples.
c Most LGV is symptomatic and no significant asymptomatic
reservoir of infection has been identified.
c Testing for chlamydia from the rectum and urethra should be
included for MSM requesting a sexual health screen, but
serovar-typing is not indicated in the absence of symptoms.
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